Last update Jan. 9, 2022
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
C22 H17 ClN2 is Clotrimazole in Molecular formula.Is written in other languages:
C22 H17 ClN2 belongs to these groups or families:
Main tradenames from several countries containing C22 H17 ClN2 in its composition:
|Oral Bioavail.||≈ 0. (Vaginal : 3 - 10)||%|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Excretion into breast milk is very unlikely since absorption through skin, vaginal mucosa, and, even intestinal mucosa into plasma is very poor with non-significant plasma levels or below the detection threshold (<10 ng/mL). (MSyC 2014, Butler 2014, Bayer 2013, Lücker 1984)
In addition, because of a high plasma protein binding capacity, excretion into breast milk seems to be less likely.
It is used frequently for treatment of Candida infection, either in skin or mouth mucosa, even in newborn and premature infants without observed side-effects. (Hoeger 2010, Dhondt 1992, Johnstone 1990, Sitka 1976, Cohen 1974)
In case of use on the nipple, do it after feeding the baby and cleanse thoroughly the surface before the next one. Do not use creams, gels and other locally applied products that contain paraffin (mineral oil) to prevent absorption by the infant. (Concin 2008, Noti 2003)